15.82
+0.32
(2.06%)
May 23 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 15.11 - 16.00 |
| 52 week | 7.55 - 20.78 |
| Open | 15.49 |
| Vol / Avg. | 270,739.00/441,180.00 |
| Mkt cap | 294.95M |
| P/E | - |
| Div/yield | - |
| EPS | -1.38 |
| Shares | 18.64M |
| Beta | 0.08 |
| Inst. own | 95% |
Events
May 16, 2013
Repros Therapeutics, Inc. at Bank of America Merrill Lynch Health Care Conference
May 10, 2013
Q1 2013 Repros Therapeutics, Inc. Earnings Release
Apr 5, 2013
Repros Therapeutics, Inc. at BioCentury Publications Future Leaders in the Biotech Industry Conference
Mar 28, 2013
Repros Therapeutics, Inc. Reports Both Primary Endpoints Successfully Met in First Pivotal Study of Androxal(R)
Mar 19, 2013
Repros Therapeutics, Inc. at Roth Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -737400.00% | -605566.70% |
| Operating margin | -737400.00% | -605566.70% |
| EBITD margin | - | -599933.30% |
| Return on average assets | -126.54% | -110.45% |
| Return on average equity | -150.43% | -131.17% |
| Employees | 26 | - |
| Carbon Disclosure Rating | - | - |
Address
SUITE B-7, 2408 Timberloch Place
THE WOODLANDS, TX 77380
United States - Map
+1-281-7193400 (Phone)
+1-281-7193446 (Fax)
THE WOODLANDS, TX 77380
United States - Map
+1-281-7193400 (Phone)
+1-281-7193446 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Repros Therapeutics, Inc. is a United States-based company that develops products and services for the management of reproductive health. The Company's products include: contraceptives, vaccines for prostate cancer, enhanced topical treatment for genital herpes as well as treatments for male and female sexual dysfunction. It focuses on the development of oral small molecule drugs to address major unmet medical needs in male and female health.
Officers and directors
| Nola E. Masterson | Independent Chairman of the Board | |
| Joseph S. Podolski | President, Chief Executive Officer, Director | |
| Katherine A. Anderson CPA | Chief Financial Officer, Chief Accounting Officer, Secretary | |
| Jaye L. Thompson Ph.D. | Senior Vice President - Clinical and Regulatory | |
| Ronald D Wiehle Ph.D | Vice President - Research & Development | |
| Saira Ramasastry | Director | |
| Daniel F Cain | Independent Director | |
| Michael G. Wyllie Ph.D. | Independent Director |